To experience fado, the mournful folk music born of Lisbon’s oldest neighbourhoods, is to tap into centuries of history and ...

One of BC’s most beloved and respected music retailers, Tapestry Music, has a new location and it's hosting a 3-day grand ...

After more than a decade, the Korean pop-rock band CNBLUE returned to Los Angeles for their VOYAGE into X North America tour ...

The latest count of votes Tuesday night had Imperial Beach Mayor Paloma Aguirre with an insurmountable lead Tuesday evening ...

Live music is still your best entertainment value, when it comes to soul-feeding and body-rumbling. Here, in no particular ...

PRICING MISSTEP Novo also drew backlash from insurers, doctors and patients for launching Wegovy in the U.S. at more than $1,300 per month, about $350 more than Ozempic.

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish ...

Novo Nordisk's press release stated that the "FDA action date to decide on the Wegovy ® oral formulation NDA will be in Q4 2025." Thus, if approved, we can expect a launch in 2026.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more ...

Novo Nordisk A/S (NYSE:NVO) announced on June 26 that it will collaborate with WeightWatchers to begin distributing the bestselling weight-loss medication Wegovy, beginning July 1.

Summary The Hims & Hers Health investment thesis remains intact, despite the Novo Nordisk partnership ending, due to not being focused on branded GLP-1s. The company has long-term business targets ...